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from oral lesions and clinical symptoms recorded. The median
age of the 4 females and 2 males was 50.5 years. All patients had
signs of OC with tongue plaques manifesting at a median of 86
days post-HCT (range 30-1045) and symptoms of dry mouth,
anorexia, nausea and/or vomiting. Dysguesia was noted in three
patients and weight loss in ﬁve (median 18 kg). None had
odynophagia and EGD performed in 3 patients was negative for
esophageal candidiasis. A total of 24 isolates were evaluated,
with those tested being resistant to ﬂuconazole, itraconazole,
and voriconazole with respective MIC’s of 256 /ml, 44 /ml
and 14.7 /ml. All isolates were sensitive to amphotericin B
(MIC 0.38 /ml). Concurrent systemic antifungal therapy at the
time of diagnosis of OC comprised: ﬂuconazole, voriconazole,
caspofungin or micafungin, or combination regimens of caspo-
fungin, micafungin, or amphotericin B lipid complex with vori-
conazole. The signs and symptoms persisted despite continua-
tion or alterations in the systemic antifungal regimen. Topical
application to the oral mucosa (5 ml 2-4 times/day) of ampho-
tericin B oral suspension (ABOS), prepared by the pharmacy at
a concentration of 100 mg/ml, resulted in dramatic clinical
response with rapid resolution of symptoms in all 6 patients. OC
relapsed at a median of 65.3 days in all the patients necessitating
re-treatment with ABOS. All patients rapidly responded. We
conclude that ABOS provides a simple, highly effective and
low-cost option for treatment of C. glabrata OC. The use of
newer antifungal agents combined with the incidence and mor-
bidity of other non-albicans OC infections may provide future
directions of study.
HCT Patient Characteristics
Age Sex Diagnosis
Transplant
Characteristics
GI
GvHD
Concurrent
Antifungal
Therapy
39 F CML-BC MRD, Cy/TBI (12
Gy)
Acute FLUC, VORI
51 M MM/PCL MRD, Flu/Mel/Cam Chronic FLUC, VORI
47 F T-ALL/AML MMUD, Cy/TBI/
Cam (12 Gy)
N/A FLUC
60 F DLBCL/NHL MUD, Flu/Mel/Cam Acute VORI, CASP,
MICA
50 F CML-BC MMUD, Flu/TBI/
Cam/CD45 (4.5
Gy)
N/A VORI, CASP,
ABLC, MICA
58 M MDS MRD, Flu/TBI/Cam
(4.5 Gy)
Chronic FLUC, VORI,
CASP, MICA
Abbreviations: CML-BC: Chronic Myelogenous Leukemia in
Blast Crisis; MM/PCL: Multiple Myeloma/ Plasma Cell Leu-
kemia; T-ALL/AML: T-cell Acute Lymphoblastic Leukemia/
Acute Myeloblastic Leukemia; DLBCL/NHL: Diffuse Large
B-cell Lymphoma/Non Hodgkin’s Lymphoma; MDS: Myelo-
dysplastic Syndrome; MRD: Matched Related Donor;
MMUD: Mis-matched Unrelated Donor; MUD: Matched Un-
related Donor; Cy: Cyclophosphamide; TBI: Total Body Irra-
diation; Flu: Fludarabine; Mel: Melphalan; Cam: Alemtu-
zumab; CD45: Investigational Anti-CD45 Monoclonal
Antibody; FLUC: Fluconazole; VORI: Voriconazole; CASP:
Caspofungin; MICA: Micafungin; ABLC: Amphotericin B
Lipid Complex
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PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED
NAUSEA AND VOMITING FOLLOWING HIGH DOSE MELPHALAN AND
AUTOLOGOUS STEM CELL TRANSPLANTATION
Triﬁlio, S.1, Pi, J.1, Fishman, M.1, Masino, K.1, Kaniecki, K.1,
Mehta, J.1 1Northwestern Memorial Hospital, Chicago, IL.
Recipients of autologous stem cell transplanatation(HSCT) with
high dose melphalan universally experience signiﬁcant acute and
delayed nausea and vomiting(N/V)(60-100%), with the number of
emetic episodes typically increasing over advancing days. Currently
no drugs with FDA approval for delayed N/V have been studied in
recipients of HSCT. Palonosetron, a serotonin antagonist(5HT3)
with a prolonged duration of action, is approved for acute and
delayed onset N/V following moderate to highly emetogenic che-
motherapy. A retrospecive study was undertaken to determine if
the type of 5HT3 used, affected the amount of N/V experienced
and the number of antiemetics used to treat breakthrough N/V.
The treatment group included 25 myeloma patients who received
0.25mg palonsetron prior to HDM followed by HSCT. Melphalan
dose(m2) 200mg(n22),140mg(n2) 100mg(n1). The control
group was comprised of 49 patients who received 24mg IV ondan-
setron prior to HDM. The groups were otherwise compara-
ble.There were no scheduled anti-emetic from day0 onwards, and
anti-emetics were administered “as needed” based on patient needs
as asssessed by nurse clinician or clinical rounds team. As needed
meds includeed lorazepam , prochlorperazine, metoclopramide,
promethazine, ondansetron alone or in combination. Evaluation of
nausea and vomiting was assessed via interview with patient and
review of input/output in medical chart.
Table 1 shows results of palonosetron versus ondansetron and
the use of breakthrough medications. There was a statistically
signiﬁcant reduction in the number of breakthrough medications
needed for both acute and delayed N/V with respect to any break-
though medications(days 1-4) or versus additional ondansetron
only((all 7days). In addition , cost analysis revealed the following-
(all quoted from Redbook 2006): Average daily cost of break-
through medications for palonosetron and ondansetron group 
$14.00 and $56.20 respectively. Average overall cost/patient(in-
cluding prevention) for palonosetron  $477 versus ondanse-
tron.$511. There were no differences in time to engraftment or
signiﬁcnat side effects between groups.
We conclude that the use of palonosetron before HDM prior to
autologous transplantation was more effective that ondansetron in
controlling acute and delayed nausea and vomiting and improving
quality of life. In addition, because of its long duration of action,
palonosetron decreased the need for additional 5HT3 antagonists
leading to overall cost savings.
Breakthrough nausea and vomiting
Day
0-HSCT
Nausea/
Vomiting
(%)
any drug used for breakthrough ondansetron used for breakthrough
Palonosetron
(n25)
Ondansetron
(n49) P-value
Palonosetron
(n25)
Ondansetron
(n49) P-value
0 7/3 30 84 <.001 0 41 <.001
1 48/26 48 78 <.024 4 51 <.001
2 60/7 66 86 <.05 11 59 <.05
3 48/10 48 92 <.001 15 59 <.05
4 55/18 66 90 <.04 11 47 <.01
5 37/7 70 84 ns 15 53 <.006
6 40/25 60 86 <.05 19 47 <.05
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VORICONAZOLE PROPHYLAXIS IN PATIENTS AT HIGH RISK FOR INVA-
SIVE FUNGAL INFECTIONS FOLLOWING ALLOGENEIC HEMATAPOETIC
STEM CELL TRANSPLANTION
Triﬁlio, S.1, Singhal, S.1, Williams, S.1, Winter, J.1, Tallman, M.1,
Gordon, L.1, Evens, A.1, Frankfurt, O.1, Pi, J.1, Mehta, J.1 1North-
western Memorial Hospital, Chicago, IL.
Voriconazole is a triazole antifungal agent with good activity
against Aspergillus spp. Standard antifungal prophylaxis at NMH
for recipients of allogeniec HSCT is itraconazole 200mg po bid.
Voriconazole 200mg po bid is substituted on day0 of transplant if
they have prior history of Aspergillus infection(secondary prophy-
laxis) or switched from itraconazole to voriconazole with receipt of
high dose steroids(methylprednisolone 2mg/kg) for GVHD. Vori-
conazole is discontinued 30 days after immunosuppression is
stopped. 80 allograft recipients who received voriconazole and in
whom complete microbiologic and pharmacokinetic data were
available were studied to determine the efﬁcacy of voriconazole in
preventing invasive fungal infections (IFI). 24 patients had no
itraconazole prophylaxis. The remainder (n56) received itracon-
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